로딩 중…
지수 로딩 중…
HLB Pep Co., Ltd.
196300· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,070+6.82%
2026-11-02
Financials
Valuation Metrics
HLB Pep Co., Ltd.'s Market Cap is ₩386B. At end of 2025 it was ₩680B. Ranked #1871 of 2,405 in KR market (top 78%), #1159 of 1,627 on KOSDAQ (top 71%), #198 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 86%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 38.64B KRW | KR#1,871/2,405 Sec#198/231 |
| Revenue | 5.54B KRW | KR#2,319/2,405 Sec#191/231 |
| Net Income | -3.19B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 49.67B KRW | KR#2,201/2,405 Sec#200/231 |
| Net Assets | 23.01B KRW | KR#2,245/2,405 Sec#209/231 |
| Employees | 83 | KR#1,781/2,405 Sec#147/231 |
| Value | ||
| P/B | 1.68x | KR#1,875/2,405 Sec#140/231 |
| P/S | 6.97x | KR#2,225/2,405 Sec#156/231 |
| FCF Yield | -27.75% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -13.86% | KR#1,997/2,405 Sec#153/231 |
| ROA | -6.42% | KR#1,986/2,405 Sec#146/231 |
| Op. Margin | -140.45% | KR#2,305/2,405 Sec#181/231 |
| Revenue Growth | 14.70% | KR#695/2,405 Sec#68/231 |
| Financial Health | ||
| Debt Ratio | 115.87% | KR#1,676/2,405 Sec#191/231 |
| Total Debt | 17.23B KRW | KR#1,426/2,405 Sec#117/231 |
| FCF | -10.72B KRW | KR#1,718/2,405 Sec#152/231 |
| Cash | 1.22B KRW | KR#2,310/2,405 Sec#219/231 |
| Current Ratio | 1.22x | KR#1,477/2,405 Sec#154/231 |
| Performance | ||
| 1Y Return | -39.25% | KR#1,650/2,405 Sec#133/231 |
| 1M Return | -11.14% | KR#1,265/2,405 Sec#122/231 |
| From 52W High | -57.29% | KR#1,525/2,405 Sec#124/231 |
| 1Y MDD | -60.48% | KR#1,467/2,405 Sec#119/231 |
| Trading | ||
| Volume | 15,247 shares | KR#1,646/2,405 Sec#161/231 |
| Trading Value | 60.1M KRW | KR#1,639/2,405 Sec#170/231 |
| Foreign Own. | 1.11% | KR#1,982/2,405 Sec#195/231 |
| Per Share | ||
| EPS | -336 KRW | KR—/2,405 Sec—/231 |
| BPS | 2,424 KRW | KR#1,983/2,405 Sec#159/231 |
Company Info
동사는 2000년 펩타이드 바이오소재 및 글로벌 혁신 신약 개발 회사로 설립됨. 의약품, 원료의약품, 의약부외품 제조·판매 및 생명공학 관련 연구개발업을 영위하며, 의약용 펩타이드 소재 40.36%, 연구용 펩타이드 소재 54.93%의 매출 비중을 보임. APsoluT 플랫폼 기술로 유방암, 위암, 대장암 신약 후보 발굴 및 네트워킹을 통한 연구개발 진행하고 있음. HLB펩는 2000년에 설립되었으며 광주광역시 북구에 본사를 두고 있습니다.